Ontario Bioscience Innovation Organization Announces Election of Arun Menawat, Jim Graziadei and Richard Meadows to its Board of Directors

PRESS RELEASE Toronto, Ontario, December 9, 2013 – Ontario Bioscience Innovation Organization (“OBIO®”), a non-profit organization that is Ontario’s leading advocate for the life science sector, announces the election of three new members to its Board of Directors: Arun Menawat, Jim Graziadei, and Richard Meadows.

“OBIO welcomes three new industry thought leaders to our Board of Directors,” said Dr. David Young, Chair of the OBIO Board of Directors. “We look forward to their contribution to OBIO’s efforts to engage stakeholders in the development of a fully functioning human health technology and bioscience ecosystem for the benefit of Ontarians and people of the world.”

“I look forward to being part of the important work of the Ontario Bioscience Innovation Organization,” said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq Technologies Inc. “OBIO’s impressive team and dedication to enabling the development and commercialization of life science technologies is helping to ensure the continued growth of Ontario’s globally competitive bioscience sector.”

In addition, OBIO is pleased to announce that Jung-Kay Chiu, Partner, Norton Rose Fulbright, will serve as Secretary for the OBIO Board of Directors.

Dr. Arun Menawat is President and Chief Executive Officer of Novadaq Technologies Inc. (NASDAQ: NVDQ, TSX: NDQ) and will serve as Vice-Chair of the OBIO Board. Dr. Menawat has been Novadaq’s President and CEO since April 2003. Previously, he held senior management positions at Cedara Software, Tenneco, Inc. and Hercules, Inc. His educational background includes a Ph.D. in Chemical Engineering from the University of Maryland, College Park, MD, including research in Biomedical Engineering from the National Institute of Health, Bethesda, MD. Dr. Menawat also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University in Evanston, IL.

Mr. Jim Graziadei is Senior Vice President of the Siemens Canada Healthcare Sector and will serve as a Director of the OBIO Board. Mr. Graziadei is responsible for the overall strategic direction and management of the Siemens Healthcare business in Canada, including the Imaging & Therapy, Clinical Products and Diagnostics divisions. Providing a full range of integrated services including multi-vendor solutions, asset planning and management, Siemens is a leading healthcare supplier and consultant in the field of image management and networking systems. Mr. Graziadei has more than 20 years of sales, marketing and management experience. Most recently he was General Manager of Siemens Diagnostics in Canada and was responsible for achieving strategic and financial goals by developing a high performance structure and culture. Mr. Graziadei holds a Bachelor of Science in Business Administration from California State University in Sacramento, CA.

Mr. Richard Meadows has been one of two managing partners at CTI Life Sciences Fund. He was formerly a successful investor at Vantage Point Venture Partners and CDP Capital Technology Ventures. Mr. Meadows was on the boards as an early investor in Enobia Pharma, which sold for $1.1 billion to Alexion Pharmaceuticals, and TargeGen which sold in June 2010 to Sanofi for $560 million. Mr. Meadows has extensive experience in operations, general management in biopharmaceuticals, and finance. He has made and managed investments in the cancer, cardiovascular, auto-inflammatory and immunology areas. Mr. Meadows was recently recognized by Forbes as one of the top 10 life science investors in 2013.

Mr. Jung-Kay Chiu practises in all areas of intellectual property law, with a focus on intellectual property acquisition, protection and exploitation in the field of biotechnology and medical devices. Mr. Chiu’s practice includes drafting and prosecuting patent applications, industrial designs and trade-marks, as well as patent licensing and other commercial transactions relating to intellectual property. Mr. Chiu is also routinely involved in preparing patent-related due diligence reports and patentability, infringement and validity opinions. Mr. Chiu joined the Norton Rose Toronto office in 2003 after practising corporate commercial law and intellectual property law with another major law firm in Canada. His technical experience includes conducting post-graduate research in molecular biology at the University of Toronto, and his technical background includes genetics, molecular biology, biotechnology and biochemistry. Mr. Chiu is Toronto Chair of the Norton Rose Intellectual Property Group.

Click here to view the full press release.